Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study

Background: High-quality diabetes care is evidence-based, timely, and equitable. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are the most recently approved class of glucose-lowering medications with additional cardio- and renal-protective benefits and low risk of hypoglycemia. Cardiovascular...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Technol Ther
Main Authors: McCoy, Rozalina G., Dykhoff, Hayley J., Sangaralingham, Lindsey, Ross, Joseph S., Karaca-Mandic, Pinar, Montori, Victor M., Shah, Nilay D.
Formato: Artigo
Idioma:Inglês
Publicado em: Mary Ann Liebert, Inc., publishers 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7207017/
https://ncbi.nlm.nih.gov/pubmed/31418588
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/dia.2019.0213
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados